Clinical Trials on Stage IIIB Non-Small Cell Lung Cancer in China

Total 1958 results

Xiaorong Dong

Recruiting

Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel in Non-squamous NSCLC After First-line Treatment

Non-small Cell Lung Cancer

China
Qianfoshan Hospital

Recruiting

Patient's Whole Process Follow-up Management(HOPE-1) (HOPE-1)

Metastatic NSCLC | Locally Advanced Non-Small Cell Lung Cancer

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Glumetinib Combined With Toripalimab in the Treatment of Relapsed or Metastatic Non-small Cell Lung Cancer. (CT32)

Relapsed or Metastatic Non-small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Completed

Immunochemotherapy or Chemotherapy in ALK-rearranged 5'-ALK NSCLC (CLASSIC5)

Non-small Cell Lung Cancer

China
Beijing Mabworks Biotech Co., Ltd.
Betta Pharmaceuticals Co., Ltd.

Completed

mil60 Versus Bevacizumab in Patients With Treatment-naïve Non-squamous Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Active, not recruiting

Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations

Non-small Cell Lung Cancer

China
West China Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC

Lung Cancer | Non Small Cell Lung Cancer | Apatinib | Combination Chemotherapy

China
Zhejiang Cancer Hospital

Unknown

Acquired Resistant Mechanism of the First-generation EGFR TKIs

Non-small Cell Lung Cancer | Aquired Resistance | EGFR TKIs

China
Zhejiang Cancer Hospital

Unknown

Comparison of Lobectomy and Segmentectomy for cT1aN0M0 Peripheral NSCLC

Non-small Cell Lung Cancer

China
Zhejiang University

Unknown

Intrapleural Administration of Bevacizumab Versus Endostar for Pleural Effusions in NSCLC

Non Small Cell Lung Cancer

China
Zhejiang University

Unknown

Continuation of TKI With or Without Chemotherapy Beyond Gradual Progression

Non Small Cell Lung Cancer

China
Guangzhou Institute of Respiratory Disease

Recruiting

To Evaluate the Safety and Tolerability of Carbognilumab Combined With Chemotherapy as the First-line Treatment for Patients With KEAP1 Mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

China
Guangzhou Institute of Respiratory Disease

Recruiting

A Single-arm Pilot Study of First-line Treatment With Carbognilumab Combined With Chemotherapy in Patients With STK11-mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Hubei Cancer Hospital

Recruiting

Omitting CTV for Locally Advanced NSCLC Responded to Immunotherapy and Chemotherapy

Non Small Cell Lung Cancer | Radiotherapy | Immunotherapy | Locally Advanced

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC)

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

China
Anhui Provincial Hospital

Recruiting

Hypofraction Radiotherapy for Locally Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer | Toxicity Due to Radiotherapy

China
Tianjin Medical University Cancer Institute and...
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043) (ALTER-L043)

Resectable Locally Advanced Non-small Cell Lung Cancer

China
Hangzhou ACEA Pharmaceutical Research Co., Ltd.
Guangdong Provincial People's Hospital

Not yet recruiting

Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation

Advanced Non-small Cell Lung Cancer

China
Zhejiang Cancer Hospital

Active, not recruiting

Serplulimab for Patients With Non-small Cell Lung Cancer (NSCLC) With TPS ≥ 50%: a Prospective, Single-center, Single-arm Phase 2 Study. (NSCLC)

Non-small Cell Lung Cancer | PDL1 Gene Mutation

China
Betta Pharmaceuticals Co., Ltd.

Completed

Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK

Solid Tumor | Non-Small Cell Lung Cancer Metastatic

China
Betta Pharmaceuticals Co., Ltd.

Unknown

Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC

Adenocarcinoma | EGFR Positive Non-small Cell Lung Cancer

China
First Hospital of Shijiazhuang City

Unknown

Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative

Carcinoma | Non-small Cell Lung Cancer | Lung Neoplasm

China
Sihuan Pharmaceutical Holdings Group Ltd.

Terminated

XZP-5809-TT1 Tablets in Patients With T790M Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

China
ZhuGuangYing
Zhejiang Cancer Hospital; 307 Hospital of PLA; Fudan University; Cancer Institute... and other collaborators

Unknown

Radiotherapy Combined With Iressa for EGFR Mutation Positive Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

China
Qianfoshan Hospital
Shandong Provincial Hospital

Not yet recruiting

Almonertinib Plus Microwave Ablation in Advanced Non-small Cell Lung Cancer (MWA)

Advanced Non Small Cell Lung Cancer

China
Yongchang Zhang

Completed

Apatinib Combined With Vinorelbine for Non-driver Gene Mutation Non-small Cell Lung Cancer

Advanced Non Small Cell Lung Cancer

China
Fuda Cancer Hospital, Guangzhou
Shenzhen Hank Bioengineering Institute

Completed

High-activity Natural Killer Immunotherapy for Small Metastases of Non-small Cell Lung Cancer

Non-small Cell Lung Cancer Metastatic

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of TQB2450 Combined With Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（NSCLC）

Non-small Cell Lung Cancer

China
Beijing Biostar Pharmaceuticals Co., Ltd.
Chengdu Biostar Pharmaceuticals

Completed

Clinical Study of Utidelone Injection in Patients With Advanced Non-small Cell Lung Cancer（NSCLC）

Advanced Non-small Cell Lung Cancer

China
Peking Union Medical College Hospital
Merck Sharp & Dohme LLC; BeyondSpring Pharmaceuticals Inc.

Recruiting

Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004) (KeyPemls-004)

Non Small Cell Lung Cancer Metastatic

China
Shanghai Chest Hospital

Not yet recruiting

To Evaluate the Efficacy of Afatinib in the Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer With NRG1 Fusion

NRG1-fused Non-small Cell Lung Cancer

China
Yantai LNC Biotechnology Singapore PTE. LTD.

Not yet recruiting

Clinical Study of 18F-Alfatide Injection PET/CT

Non-Small Cell Lung Cancer NSCLC

China
Chongqing University Cancer Hospital
Army Specialty Medical Center; The Second Affilicated Hospital of Chongqing...

Recruiting

First-line Furmonertinib in Advanced NSCLC Patients With EGFR Uncommon Mutation

Non-small Cell Lung Cancer | EGFR G719X | EGFR L861Q | EGFR S768I

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy

Locally Advanced Non-Small Cell Lung Cancer

China
GeneCast Biotechnology Co., Ltd.
Wuhan University; Southwest Hospital, China; Tongji Hospital; The First Affiliated... and other collaborators

Terminated

Multi-Omics Testing for Immunotherapy Efficacy Evaluation (MOTIVATION) (MOTIVATION)

Non-small Cell Lung Cancer | Biomarker | Next-generation Sequencing | Neoantigen

China
Cancer Institute and Hospital, Chinese Academy...

Unknown

TKI Followed by Thoracic Radiotherapy for Stage IV EGFR Mutant NSCLC

Non-Small Cell Lung Cancer Metastatic

China
Fudan University

Unknown

Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small Cell Lung Cancer Patients

Non-small Cell Lung Cancer | Toxicity

China
Guangdong Provincial People's Hospital

Recruiting

Liquid Biopsy in Advanced Oligometastatic NSCLC Receiving Surgery

Non-small Cell Lung Cancer | Oligometastatic Disease

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

To Compare the Efficacy and Safety of BP102 vs. Avastin® in Combination With Paclitaxel/Carboplatin in First-line Treatment of Advanced or Relapsed NSCLC

Non-small Cell Lung Cancer(NSCLC)

China
Shanghai Henlius Biotech

Recruiting

A Study of HLX07 + HLX10 With or Without Chemotherapy Versus HLX10 With Chemotherapy in First Line sqNSCLC

Squamous Non-small-cell Lung Cancer

China
Tang-Du Hospital

Active, not recruiting

Camrelizumab Combined With Albumin-bound Paclitaxel and Platinum in Neoadjuvant Treatment of Resectable NSCLC

Non-small-cell Lung Cancer (NSCLC)

China
Hoffmann-La Roche

Completed

Disease Characteristics, Treatment Patterns and Clinical Outcomes in Patients With Newly Diagnosed Unresectable Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) in China

Non-Small Cell Lung Cancer, Lung Cancer, Cancer

China
Hunan Province Tumor Hospital

Completed

Correlation Research of Thioredoxin Reductase in Lung Cancer (TRCRLC)

Non-small Cell Lung Cancer | Benign Neoplasm of Lung

China
Hunan Province Tumor Hospital

Not yet recruiting

Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW (WUKONG-32-RW)

Non-small Cell Lung Cancer

China
Guangdong Provincial People's Hospital

Recruiting

Neoadjuvant Immunotherapy in EGFR-mutant Localized NSCLC (NEOTIDE)

Non-small Cell Lung Cancer | EGFR Activating Mutation

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer

Non Small Cell Lung Cancer

China
Eli Lilly and Company

Completed

A Study Comparing Two Different Chemotherapy Types in Chinese Patients With Advanced Non Small Cell Lung Cancer

Non Small Cell Lung Cancer

China
Shanghai Pulmonary Hospital, Shanghai, China

Terminated

Neoadjuvant PD-1 Antibody Plus Chemotherapy in Resectable Stage IIIA-N2 Non-Small-Cell Lung Cancer

Non Small Cell Lung Cancer

China
Chinese Society of Lung Cancer

Completed

Study of Pemetrexed Versus Gefitinib in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy Without Epidermal Growth Factor Receptor (EGFR) Mutations

Non Small Cell Lung Cancer

China
The First Hospital of Jilin University

Completed

Natural Killer(NK) Cell Combined With Programmed Death-1(PD-1) Antibody as Second Line Therapy for Advanced Driver Mutation Negative Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China

Clinical Trials on Stage IIIB Non-Small Cell Lung Cancer in China

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Costa Rica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations